CYB003

Cybin's CYB003, also called deupsilocin, is a deuterium-modified version of psilocin (the active metabolite of psilocybin) now in Phase 3 for major depressive disorder as adjunctive therapy. The commercial pitch is a shorter, more predictable psychedelic session of roughly 90 minutes versus 4 to 6 hours for standard psilocybin, which could make clinic-based dosing economically viable at scale. Cybin IRL is running two Phase 3 trials (NCT06564818 and NCT06793397) with MADRS as the primary endpoint, and this is the lead asset at Cybin Inc. (NYSE American: CYBN) [1][2].

Novel compound, never approved anywhere. The Phase 3 program is run under two protocols: NCT06564818 (listed as completed, n=223) and NCT06793397 (recruiting, n=330), both sponsored by Cybin IRL Limited and both using the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary endpoint [1][2]. A Phase 1 study (NCT05385783, n=57) completed in healthy volunteers and patients with MDD characterized safety and PK [3]. The FDA granted Breakthrough Therapy Designation for CYB003 in MDD in March 2024, which is a meaningful signal the agency saw Phase 2 data as potentially class-leading [4]. Cybin disclosed Phase 2 MADRS separation of double-digit points versus placebo at the 16 mg dose at week 3 after a two-dose regimen, with durability reported out to week 12 in a small cohort [5]. Phase 3 topline readouts are guided for 2026-2027 depending on protocol. Cybin raised capital in 2024 and 2025 to fund the Phase 3 program through readout [6].

Serotonin is a brain chemical that influences mood, perception, and cognition. The 5-HT2A receptor is one of serotonin's docking sites, concentrated in the cortex. Classic psychedelics (psilocybin, LSD, DMT) all activate 5-HT2A, and that activation drives both the acute psychedelic experience and, in multiple controlled trials, durable antidepressant effects after one or two sessions [7]. Deupsilocin is psilocin with heavy hydrogen (deuterium) swapped in at specific positions on the molecule. Deuterium bonds are harder for metabolic enzymes to break than ordinary hydrogen bonds, so the body chews through the drug more slowly in a specific, predictable way. The result is a tighter plasma curve and a shorter trip, roughly 90 minutes of acute effects versus 4 to 6 hours for psilocybin, at the same receptor with the same downstream signaling. The target is well-validated by human efficacy data: psilocybin has shown MADRS reductions comparable to or exceeding SSRIs in head-to-head work [7], and the open question for the class is magnitude and durability at Phase 3 scale, not whether 5-HT2A agonism does something to depression.

NCT06564818 is a Phase 3, randomized, placebo-controlled, adjunctive-therapy study in adults with MDD, n=223, primary endpoint change from baseline in MADRS score [1]. NCT06793397 is a parallel Phase 3 (n=330, recruiting) with the same core design [2]. MADRS is a 10-item clinician-rated depression scale running 0 to 60; a 2 to 3 point separation versus placebo is generally considered clinically meaningful at the regulatory level. The adjunctive design, patients remain on their existing antidepressant and receive CYB003 on top, has a design advantage over monotherapy psilocybin studies: the placebo arm is less likely to show dramatic improvement because these patients have already demonstrated inadequate response. Concerns: functional unblinding is a known problem for all psychedelics because patients can tell whether they got active drug based on subjective effects, which can inflate placebo-adjusted scores. The Phase 3 structure uses straight placebo rather than an active low-dose comparator, which is simpler but exposes the trial to unblinding criticism at FDA review. Enrollment velocity on NCT06793397 is the operational metric to watch; a stall there would delay the second confirmatory readout.

Our model estimates a 10% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 51%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy: Phase 3 is where psychedelic effect sizes have historically shrunk. If deupsilocin's shorter session also shortens the window of durable antidepressant effect, the drug could underperform psilocybin on sustained MADRS improvement at weeks 6 and 12. Compass's COMP360 Phase 3 topline hit its primary at week 6 but had messy secondary and durability readouts [9], a cautionary data point for the class. Safety: Acute psychiatric adverse events (anxiety, dissociation, treatment-emergent suicidality signals) are category concerns the FDA scrutinizes heavily. Headache and transient hypertension during the acute phase have been reported for 5-HT2A agonists. The shorter session partly mitigates monitoring burden but does not eliminate the signal risk. Execution: Cybin is a small clinical-stage company with limited cash runway, and dilutive financing before Phase 3 topline is a real possibility that would compress returns even on a positive readout [6]. Commercial: Even if approved, the drug requires in-clinic administration with a trained monitor, same model as Spravato. REMS program design, payer coverage decisions, and clinic buildout will drive adoption. Spravato grew to roughly $1.0B in 2024 revenue for J&J, five years after approval [11], which is the realistic pace reference. Deupsilocin's shorter session is the differentiator because clinic economics depend on patients-per-chair-per-day.

Worth watching. The 90-minute session versus 4 to 6 hours is a commercially meaningful lever if efficacy holds, because clinic throughput is the binding constraint on psychedelic therapy economics. The signal that matters is the Phase 3 topline from NCT06564818: magnitude of MADRS separation at the primary timepoint, durability out to weeks 6 and 12, and discontinuation rates will determine whether this is a $500M peak-sales drug or a $3B+ one. Cybin (CYBN) trades as a volatile microcap, so if APPROACH topline reads positive and clean, the stock re-rates sharply; a miss or Compass-style messy data brings substantial downside. The company's cash position and any raise cadence are the overlay. Check back when the Phase 3 topline is reported, guided for 2026-2027. Interim operational indicators: NCT06793397 enrollment pace in Cybin's quarterly updates (a slowdown suggests site capacity issues or field skepticism), Cybin's cash runway in each 10-Q filing (a raise before readout compresses returns on a win), and any FDA guidance or type-C meeting disclosures around psychedelic trial design in the wake of the Lykos complete response letter [10].